U.S. Markets open in 7 hrs 4 mins

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.30-0.60 (-5.04%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.90
Open11.79
Bid0.00 x 1100
Ask0.00 x 1400
Day's Range10.75 - 11.79
52 Week Range7.80 - 28.71
Volume214,024
Avg. Volume134,338
Market Cap247.033M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateDec 03, 2020 - Dec 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.35
  • The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
    Benzinga

    The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Athira Pharma Inc (NASDAQ: ATHA) * Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) - announced a deal to be bought by Endo International PLC (NASDAQ: ENDP) for $658 million or $88.50 per share in cash * Blueprint Medicines Corp (NASDAQ: BPMC) * CymaBay Therapeutics Inc (NASDAQ: CBAY) * Eidos Therapeutics Inc (NASDAQ: EIDX) * Forma Therapeutics Holdings Inc (NASDAQ: FMTX) * Immunomedics, Inc. (NASDAQ: IMMU) * Insmed Incorporated (NASDAQ: INSM) * Kymera Therapeutics Inc (NASDAQ: KYMR) * Larimar Therapeutics Inc (NASDAQ: LRMR) * Mirati Therapeutics Inc (NASDAQ: MRTX * Nevro Corp (NYSE: NVRO) * Pacific Biosciences of California Inc (NASDAQ: PACB) * Shockwave Medical Inc (NASDAQ: SWAV) * Tarsus Pharmaceuticals Inc (NASDAQ: TARS) (listed on Nasdaq Friday)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 19) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) * Dyne Therapeutics Inc (NASDAQ: DYN) * Gilead Sciences, Inc. (NASDAQ: GILD) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Opthea Limited (NASDAQ: OPT) (listed on Nasdaq Friday) * ProQR Therapeutics NV (NASDAQ: PRQR) * Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP)Stocks In Focus Aptinyx's NYX-783 Aces Midstage Study In Post-Traumatic Stress Disorder Aptinyx Inc (NASDAQ: APTX) announced positive results from the first Phase 2 study of its novel NMDA receptor modulator, NYX-783, in 153 patients with post-traumatic stress disorder.In the Phase 2 study, NYX-783 demonstrated statistically significant and clinically meaningful efficacy results and a favorable adverse event and tolerability profile, the company said.Based on these results, the company said it expects to initiate a pivotal study in 2021.The stock was jumping 92.35% to $7.04 premarket Tuesday.Cara Therapeutics Grants Vifor US License For Korsuva In Deal Valued Up To $440M Cara Therapeutics Inc (NASDAQ: CARA) and Vifor Pharma announced the signing of a license agreement for the commercialization of Korsuva injection for the treatment of chronic kidney disease associated with pruritus.Cara provided Vifor with the commercial rights for IV Korsuva in the non-Fresenius Medical Care dialysis clinics, with the agreement giving Cara a 60% share of the profit and Vifor 40%.Under the terms of the agreement, Cara will also receive an upfront payment of $100 million in cash and an equity investment of $50 million. In addition, Cara will be eligible to receive an additional equity investment upon U.S. regulatory approval of IV Korsuva, as well as milestone payments dependent on achieving commercial targets, which together could total up to $290 million.In premarket trading Tuesday, Cara shares were jumping 16.65% to $16.25.Centogene Raises FY20 Guidance Due On COVID-19 Testing, Recovery In Core Business Centogene NV (NASDAQ: CNTG) said it is increasing its full-year 2020 guidance from 60-65 million euros ($70.8 million to $75.6 million) to greater than 80 million euros.The company attributed the positive expectation to further developments in its commercial COVID-19 testing and the continued recovery of its core business since the second quarter.Separately, the company announced that CEO Arndt Rolfs is stepping down. Centogene is appointing Andrin Oswald as CEO effective Dec. 1. The stock was adding 4.77% to $12.75 premarket Tuesday.Related Link: The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference Merck Reports Positive Data For 2 Late-Stage Studies Of Pneumococcal Conjugate Vaccine Merck & Co., Inc. (NYSE: MRK) announced positive findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, its investigational 15-valent pneumococcal conjugate vaccine.Merck shares were up 0.47% to $79.04 premarket Tuesday.Cleveland BioLabs To Merge With Privately Held Cytocom In All-Stock Transaction Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced a definitive merger agreement to combine its business with Cytocom in an all-stock transaction.Cytocom shareholders will have a majority position in the newly combined entity. The shares will continue to be listed on the Nasdaq, and the initial board for the combined company will consist of four members selected by Cytocom and three members selected by Cleveland BioLabs. The boards of both companies have approved the combination.In premarket trading Tuesday, Cleveland shares were up 68.66% to $3.66.Inventiva Gets Fast Track Designation For Metabolic Disorder Drug Inventiva ADR Representing Ord Shs (NASDAQ: IVA) said the FDA has granted fast track designation to odiparcil, its clinical-stage drug candidate for the treatment of mucopolysaccharidoses type VI, a rare and progressive genetic disorder.In premarket trading Tuesday, the stock was up 5.59% to $14.35.Oric Pharma In-Licenses Genetic Cancer Drug ORIC Pharmaceuticals Inc (NASDAQ: ORIC) said it has entered into an exclusive license agreement with Voronoi to secure exclusive rights worldwide -- excluding China, Hong Kong, Macau and Taiwan -- for the development and commercialization of ORIC-114.The drug is a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency against exon 20 insertion mutations.ORIC said it expects to initiate a global Phase 1/2 tumor-agnostic trial in genetically defined cancers during the second half of 2021.CytoDyn Says Data Monitoring Committee Recommends Continuation Of Registrational Late-Stage COVID-19 Study CytoDyn Inc (OTC: CYDY) said that following a first interim analysis, the Data Safety Monitoring Committee that reviewed data from its Phase 2b/3 registrational trial of leronlimab in patients with severe-to-critical COVID-19 recommended that the trial continue without modification to achieve the primary endpoint.The committee also requested another interim analysis when enrollment reaches the 75% level.Offerings BELLUS Health Inc (NASDAQ: BLU) said it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and LifeSci Capital, relating to the public offering of 15.56 million common shares.The shares are being sold at a public offering price of $2.25 per common share.The stock was down 0.43% at $2.31 premarket Tuesday.On The Radar PDUFA Dates Zosano Pharma Corp's (NASDAQ: ZSAN) NDA for its migraine drug Qtrypta has a PDUFA action date of Oct. 20. With the company disclosing in late September that it has received a discipline review letter, which raised two concerns about the clinical pharmacology section of the NDA, a decision Tuesday seems unlikely.Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs * The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • CENTOGENE Announces Leadership Transition
    GlobeNewswire

    CENTOGENE Announces Leadership Transition

    CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that Prof. Arndt Rolfs, the Company’s Chief Executive Officer (CEO) and founder, has decided to step down as CEO of CENTOGENE as of October 20, 2020, and that Andrin Oswald, M.D., will join the Company as CEO on December 1, 2020. Prof. Rolfs has agreed to serve as an advisor during the transition period. “I am pleased to join CENTOGENE at such an exciting time in the Company’s evolution,” said Dr. Oswald. “With Prof. Arndt Rolfs’ leadership, CENTOGENE has created a unique proprietary platform focused on improving medical diagnosis and delivering better outcomes for patients with rare diseases. I look forward to leading the Company’s continued expansion and leveraging its superior disease insights to help develop life-changing therapies for the many patients affected by thousands of rare and often devastating illnesses.”“Dr. Oswald is an accomplished leader in healthcare with a strong track record of building global companies focused on purpose, innovation and excellence,” said Dr. Flemming Ørnskov, Chairman of CENTOGENE’s Supervisory Board. “With his extensive, over 20-year professional experience across the life sciences, including in diagnostics and pharmaceuticals, he brings valuable experience and knowledge as well as an extensive network which can contribute to further scaling and accelerating CENTOGENE’s growth as a leader in the rare diseases space.”Dr. Ørnskov continued, “On behalf of the Supervisory Board and all employees, I’d like to thank Arndt for everything he has helped CENTOGENE achieve over the last 16 years, and we are pleased that he will remain available to us as an advisor during the transition period. Arndt has been instrumental in building CENTOGENE’s unique capabilities, including its vast and complex biological data resources in rare diseases which enable better and faster clinical diagnoses and drug development. His unique expertise and personal drive have created significant value for patients and positioned the Company for continued growth and success, and we are grateful for his guidance and support in preparing for this transition.”Under Prof. Rolfs’ leadership, CENTOGENE has evolved from its inception in 2006 into what is now the world’s leading partner and knowledge resource for diagnosis and research around rare diseases. CENTOGENE is a global company that employs over 500 experts and contributors from over 50 nations and helps transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies.“It has been a great honor to lead this groundbreaking Company for 16 years, and I am proud of all we as a team have accomplished for patients with rare genetic diseases around the world,” commented Prof. Arndt Rolfs. “CENTOGENE has a clear mission and a committed and excellent team that will help drive a very exciting future for the Company. Our recently updated guidance speaks to the team’s so valuable contributions and the strength and agility of the business, which continues to recover nicely from the impact of COVID-19. I have decided that the Company is now in a great position to enter into a new phase of its journey and that this is a good time to allow new leadership to shape its future. I intend to participate in its future as a shareholder and look forward to working closely with the management team to ensure a smooth transition for the benefit of our patients, employees, partners, shareholders, and other stakeholders, as CENTOGENE continues to play a critical role in how we diagnose and treat rare diseases.”Additional Background on Andrin Oswald, MDDr. Oswald was most recently the Delegate for COVID-19 Vaccines and Immunotherapies for the Federal Government of Switzerland, helping develop response and procurement strategies while advising the Swiss government on key decisions.Prior to that, he was Director of Life Science Industry Engagement and Partnerships at the Bill & Melinda Gates Foundation, a role he held for four years in which he led the Foundation’s engagement with the industry and supported teams in developing and advancing its Global Health and Development priorities in R&D and delivery technologies. Prior to his role at the Bill & Melinda Gates Foundation, he oversaw business integration at GlaxoSmithKline, working directly with the CEO to advise on business and integration strategy. Before joining GlaxoSmithKline, Dr. Oswald spent more than 10 years in a variety of leadership roles at Novartis, including serving as Assistant to the Chairman and CEO of Novartis International AG; Country President for Novartis South Korea; Head of Global Development Franchises and a member of the Executive Committee for Novartis Pharma; and ultimately, CEO/Division Head of Novartis Vaccines & Diagnostics and a member of the Novartis Executive Committee, based in Boston. Dr. Oswald began his career in 1999 with McKinsey & Company, where he worked in various roles managing relationships and supporting projects with leading pharmaceutical and diagnostics companies in Europe and the U.S.Throughout his career Dr. Oswald has also served on several boards, including the Novartis Foundation for Sustainable Development in Basel, Switzerland; the Global Health Innovation Technology Fund in Tokyo, Japan; and the Global Health Investment Corporation, where he was also a founding member.About CENTOGENECENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.6 billion weighted data points from approximately 570,000 patients representing over 120 different countries as of August 31, 2020.The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of August 31, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.Important Notice and Disclaimer This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and govern-mental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020, Form 6-K containing our financial results for the three months ended March 31, 2020, filed with the SEC on June 15, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. CONTACT: Media Contact: CENTOGENE Sun Kim Chief Strategy and Investor Relations Officer investor.relations@centogene.com FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com

  • CENTOGENE Increases Full-Year 2020 Guidance
    GlobeNewswire

    CENTOGENE Increases Full-Year 2020 Guidance

    CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced it is increasing full-year 2020 guidance and now anticipates revenues greater than €80 million. Prior guidance had anticipated revenues of between €60 - €65 million. This update follows the further developments in our commercial Covid-testing and the continued recovery of our core business since Q2. Richard Stoffelen, Chief Financial Officer of CENTOGENE, said, “Our core business is recovering after the significant pandemic-induced decline in Q2. In addition, we saw a significant increase in our Covid-testing revenue in recent months. We look forward to maintaining this momentum throughout the remainder of 2020, all while helping to ensure the health and safety of our team, customers, and partners around the world.”The Company will continue to closely monitor the outlook for the remainder of 2020.About CENTOGENE CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.6 billion weighted data points from approximately 570,000 patients representing over 120 different countries as of August 31, 2020. The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of August 31, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases. Important Notice and Disclaimer This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and govern-mental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2019 on Form 20-F filed with the SEC on April 23, 2020, Form 6-K containing our financial results for the three months ended March 31, 2020, filed with the SEC on June 15, 2020 and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. CONTACT: Media Contact: CENTOGENE Sun Kim Chief Strategy and Investor Relations Officer investor.relations@centogene.com FTI Consulting Bridie Lawlor +1.917.929.5684 bridie.lawlor@fticonsulting.com